MAP2K1 and neoplasm: Since the changes in immune cells described above cannot be definitively attributed to EVs, we repeated the experiment but with 9609 tumours that were co‐injected and treated with vehicle control, MEK1‐low EVs, or MEK1‐hi EVs.